Edition:
United States

Tocagen Inc (TOCA.OQ)

TOCA.OQ on NASDAQ Stock Exchange Global Select Market

12.39USD
16 Feb 2018
Change (% chg)

$0.05 (+0.41%)
Prev Close
$12.34
Open
$12.27
Day's High
$12.72
Day's Low
$12.27
Volume
37,290
Avg. Vol
68,765
52-wk High
$17.75
52-wk Low
$8.64

Chart for

About

Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to... (more)

Overall

Beta: --
Market Cap(Mil.): $245.44
Shares Outstanding(Mil.): 19.81
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Tocagen Estimates Cash, Cash Equivalents And Marketable Securities About $89.0 Million As Of Dec 31, 2017

* TOCAGEN SAYS ESTIMATE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE ABOUT $89.0 MILLION AS OF DEC 31, 2017 - SEC FILING

Jan 08 2018

BRIEF-Tocagen Q3 loss per share $0.50

* Tocagen reports third quarter 2017 financial and business results

Nov 08 2017

BRIEF-Tocagen to accelerate Toca 511 & Toca FC development into Phase 3 trial

* Tocagen to accelerate Toca 511 & Toca FC development into pivotal Phase 3 trial Source text for Eikon: Further company coverage:

Oct 26 2017

Competitors

Earnings vs. Estimates